Compare NREF & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NREF | ELTX |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.2M | 209.9M |
| IPO Year | N/A | 2014 |
| Metric | NREF | ELTX |
|---|---|---|
| Price | $13.15 | $11.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $14.50 | ★ $17.00 |
| AVG Volume (30 Days) | 47.9K | ★ 131.0K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | ★ 14.94% | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | $24.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.14 | $4.60 |
| 52 Week High | $16.80 | $14.93 |
| Indicator | NREF | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.46 | 55.17 |
| Support Level | $12.36 | $7.78 |
| Resistance Level | $15.25 | $11.82 |
| Average True Range (ATR) | 0.43 | 1.25 |
| MACD | -0.17 | -0.11 |
| Stochastic Oscillator | 3.74 | 23.76 |
NexPoint Real Estate Finance Inc is a real estate investment trust. The company provides structured financing solutions by investing in mid-sized multifamily, storage and select-service, and extended-stay hospitality properties. Its investment objective is to generate attractive, risk-adjusted returns for stockholders over the long term. The Company is focused on originating, structuring and investing in first-lien mortgage loans, mezzanine loans, preferred equity, convertible notes, multifamily properties, and common equity investments, as well as multi-family and single-family rental ("SFR") commercial mortgage-backed securities securitizations ("CMBS securitizations"), multifamily structured credit risk notes ("MSCR Notes") and mortgage-backed securities.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.